Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Combination Therapy

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

The approach starts immunotherapy before a chemoembolization procedure to help keep tumors in check earlier.

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

Single Daily Bictegravir–Lenacapavir Pill Matches Complex HIV Regimens in Phase III

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Gilead’s BIC/LEN HIV Tablet Matches Biktarvy in Phase 3 Switch Trial

Zymeworks Shifts to Royalty Model After Ziihera’s Phase 3 Win in HER2‑Positive Gastroesophageal Cancer

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

Padcev and Keytruda Combo Extends Survival in Bladder Cancer Trial

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials